Patents Assigned to Oneodrek Inc.
  • Patent number: 11885808
    Abstract: High levels of nuclear NMT1 are associated with longer relapse free survival in ER? positive breast cancer patients. Both low levels of cytosolic and nuclear NMT1 correlated to very poor clinical outcomes. NMT2 also plays an important function in breast cancer signalling, regulated through phosphorylation. For example, NMT2 phosphorylation status is a key element in the progression of ER+ breast cancer cells. Specifically, nuclear localization of NMT2 is associated with poor outcomes in breast cancer patients.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: January 30, 2024
    Assignee: Oneodrek Inc.
    Inventor: Anuraag Shrivastav